Welcome to the e-CCO Library!

P610: Penetration, short- and long-term efficacy of anti-TNF-α therapy for ulcerative colitis between 2010–2016 in Hungary
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

T. Molnár*1, F. Nagy1, Z. Szepes1, K. Farkas1, R. Bor1, A. Bálint1, Á. Milassin1, A. Fábián1, M. Rutka1, K. Szántó1

Created: Friday, 22 February 2019, 9:41 AM
P610: Real-world effectiveness and safety of advanced therapies for the treatment of moderate-to-severe ulcerative colitis (UC): evidence from a systematic literature review (SLR)
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Irving, P.M.(1);Hur, P.(2)*;Gautam, R.(3);Guo, X.(4);Vermeire, S.(5);
Created: Friday, 14 July 2023, 11:05 AM
P610: Risk of active Hepatitis B and C infections in the Phases 2 and 3 clinical trial programmes for ustekinumab
Year: 2018
Source: ECCO '18 Vienna
Authors:

R. Gish1, P. Ramachandran2, W. Xu2, S. Sloan2*

Created: Thursday, 21 February 2019, 9:14 AM
P610: Safety of COVID-19 vaccine in patients with Inflammatory Bowel Disease: preliminary data of a national study (ESCAPE-IBD)
Year: 2022
Source: ECCO'22
Authors: Todeschini, A.(1);Macaluso, F.S.(2);Contaldo, A.(3);Mannino, M.(2);Orlando, A.(2);Principi, M.(1);
Created: Friday, 11 February 2022, 3:56 PM
P611 Provision of care for pregnant women with IBD in the UK - the current landscape
Year: 2020
Source:

ECCO'20 Vienna

Authors:

E. Moore1, S. Wolloff1, T. Glanville2, C.P. Selinger1

Created: Thursday, 30 January 2020, 10:12 AM
P611: A real-world assessment of golimumab effect on quality of life, healthcare resource utilisation and work productivity in patients with ulcerative colitis in Greece: interim results from the GO-LIFE study
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

G. Mantzaris*1, A. Gatopoulou2, D. Christodoulou3, K. Katsanos3, I. Mouzas4, M. Tzouvala5, G. Paspatis6, K. Thomopoulos7, S. Michopoulos8, G. Koujlakis9, I. Pachiadakis10, K. Triantafyllou11, P. Karatzas12, D. Moschovis13, G. Theocharis7, M. Tampaki14

Created: Friday, 22 February 2019, 9:41 AM
P611: COMPARATIVE EFFECTIVENESS AND SAFETY OF VEDOLIZUMAB VS. ANTI-TNFs IN CROHN'S DISEASE BIO-NAÏVE PATIENTS AND PATIENTS WITH FAILURE OF ONE PREVIOUS ANTI-TNFα (EVOLVE-IBERIA STUDY)
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Muñoz Nuñez, J.F.(1)*;Rodríguez, C.(2);Gisbert, J.P.(3);Bernardo, S.(4);Aparicio, J.(5);Tagarro, I.(5);Casellas, F.(6);
Created: Friday, 14 July 2023, 11:05 AM
P611: Incidence, clinical presentation, and severity of SARS-CoV-2 infection in IBD patients in the second and the third wave of infection
Year: 2021
Source: ECCO'21 Virtual
Authors: Algaba Garcia, A.(1);Guerra, I.(1);Castro, S.(2);Jiménez, L.(1);Garza, D.(1);Aller, M.D.M.(1);Granja, A.(1);Guardiola, A.(1);Bellart, M.(2);Pizarro, N.(2);Bermejo, F.(1);
Created: Wednesday, 2 June 2021, 4:12 PM
P611: Outcome in ulcerative colitis after switch from subcutaneous anti-TNF to intravenous anti-TNF: A multicentre study
Year: 2018
Source: ECCO '18 Vienna
Authors:

A. Viola1*, D. Pugliese2, S. Renna3, F. Furfaro4, F. Caprioli5, R. D'Inca'6, F. Bossa7, G. Costantino1, M. Fantini8, G. Fiorino4, A. Armuzzi2, A. Orlando3, W. Fries1

Created: Thursday, 21 February 2019, 9:14 AM
P611: Relapse risk and predictors for relapse in a real-life cohort of IBD patients after discontinuation of anti-TNF therapy
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Bots S., Kuin S., Ponsioen C., van den Brink G., Löwenberg M., D'Haens G.

Created: Wednesday, 20 February 2019, 10:36 AM
P611: Serological biomarkers of type VI and XXII collagen formation predict and monitor infliximab treatment response in patients with Crohn’s disease
Year: 2022
Source: ECCO'22
Authors: Sorokina Alexdóttir, M.(1);Bourgonje, A.R.(2);Karsdal, M.A.(1);Bay-Jensen, A.C.(1);Pehrsson, M.(1);Loveikyte, R.(2);van Dullemen, H.M.(2);Visschedijk, M.C.(2);A. M. Festen, E.(2); Weersma, R.K.(2);Faber, K.N.(2);Dijkstra, G.(2);Mortensen, J.H.(1);
Created: Friday, 11 February 2022, 3:56 PM
P612 Dietary practices and beliefs of British South Asians with inflammatory bowel disease: A prospective UK study
Year: 2020
Source:

ECCO'20 Vienna

Authors:

B. Crooks1, J. McLaughlin2, J.K. Limdi1

Created: Thursday, 30 January 2020, 10:12 AM
P612: Exclusive enteral nutrition in adults with active Crohn's disease is associated with decreased disease activity
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Pfeffer-Gik T., Yanai H., Godny L., Ron Y., Maharshak N., Dotan I.

Created: Wednesday, 20 February 2019, 10:36 AM
P612: Lack of seroconversion following COVID-19 vaccination, but not treatment, is an independent risk factor for breakthrough SARS-CoV-2 infection in patients with inflammatory bowel disease: data from ESCAPE - an IG-IBD Study
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Macaluso, F.S.(1)*;Principi, M.(2);Facciotti, F.(3);Contaldo, A.(4);Todeschini, A.(5);Bezzio, C.(6);Saibeni, S.(6);Castiglione, F.(7);Nardone, O.M.(7);Spagnuolo, R.(8);Fantini, M.C.(9);Riguccio, G.(10);Conforti, F.S.(11);Caprioli, F.A.(11);Viganò, C.(12);Felice, C.(13);Fiorino, G.(14);Correale, C.(15);Bodini, G.(16);Milla, M.(17);Scardino, G.(18);Vernero, M.(19);Desideri, F.(20);Bossa, F.(21);Guerra, M.(21);Ventimiglia, M.(22);Mannino, M.(1);Rizzo, G.(23);Orlando, A.(1);
Created: Friday, 14 July 2023, 11:05 AM
P612: Long-term outcomes of treatment intervention according to the severity of small bowel capsule endoscopy findings in patients with Crohn’s disease: A Japanese single-centre cohort study
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

M. Nasuno*1, H. Tanaka1, K. Sugiyama1, M. Miyakawa1, S. Motoya1

Created: Friday, 22 February 2019, 9:41 AM
P612: Lower incidence of COVID-19 in patients with Inflammatory Bowel Diseases treated with non-gut-selective biologic therapy: an observational multicentre study.
Year: 2021
Source: ECCO'21 Virtual
Authors: Ferretti, F.(1);Monico, M.C.(1);Carvalhas Gabrielli, A.M.(1);Carmagnola, S.(1);Bezzio, C.(2);Saibeni, S.(2);Bosani, M.(3);Caprioli, F.(4);Mazza, S.(4);Casini, V.(5);Cortelezzi, C.(6);Parravicini, M.(6);Cassinotti, A.(6);Cosimo, P.(7);Indriolo, A.(7);Di Sabatino, A.(8);Lenti, M.V.(8);Pastorelli, L.(9);Conforti, F.(9);Ricci, C.(10);Sarzi-Puttini, P.(11);Vecchi, M.(4);Maconi, G.(1);Ardizzone, S.(11);
Created: Wednesday, 2 June 2021, 4:12 PM
P612: Mirikizumab Pharmacokinetics and Exposure - Efficacy Relationships in Patients with Ulcerative Colitis
Year: 2022
Source: ECCO'22
Authors: Friedrich, S.(1);Chua, L.(1);Tuttle, J.L.(2);Feagan, B.G.(3);Sandborn, W.J.(4);
Created: Friday, 11 February 2022, 3:56 PM
P613 Use of adalimumab biosimilar ABP 501 in Crohn’s disease: A real-life experience
Year: 2020
Source:

ECCO'20 Vienna

Authors:

D.G. Ribaldone1, M. Vernero2, R. Pellicano3, M. Morino1, G.M. Saracco4, M. Astegiano3

Created: Thursday, 30 January 2020, 10:12 AM
P613: Comparative objective effectiveness of vedolizumab and ustekinumab in a real-life cohort of active Crohn’s disease patients failure to TNF inhibitors.
Year: 2022
Source: ECCO'22
Authors: Onali, S.(1);Pugliese, D.(2);Caprioli, F.A.(3);Orlando, A.(4);Biancone, L.(5);Nardone, O.M.(6);Imperatore, N.(7);Fiorino, G.(8);Cappello, M.(9);Viola, A.(10);Principi, M.B.(11);Bezzio, C.(12);Aratari, A.(13);Carparelli, S.(14);Mazzuoli, S.(15);Manguso, F.(7);Grossi, L.(16);Bodini, G.(17);Ribaldone, D.(18);Mocci, G.(19);Minerba, L.(20);Favale, A.(21);Grova, M.(22);Scucchi, L.(23);Segato, S.(24);Fries, W.(25);Castiglione, F.(26);Armuzzi, A.(2);Fantini, M.C.(27);
Created: Friday, 11 February 2022, 3:56 PM